JP7412424B2 - Lpaアンタゴニストとしてのオキサビシクロ酸 - Google Patents

Lpaアンタゴニストとしてのオキサビシクロ酸 Download PDF

Info

Publication number
JP7412424B2
JP7412424B2 JP2021515046A JP2021515046A JP7412424B2 JP 7412424 B2 JP7412424 B2 JP 7412424B2 JP 2021515046 A JP2021515046 A JP 2021515046A JP 2021515046 A JP2021515046 A JP 2021515046A JP 7412424 B2 JP7412424 B2 JP 7412424B2
Authority
JP
Japan
Prior art keywords
lpa
independently
alkyl
mmol
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021515046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500473A5 (cg-RX-API-DMAC7.html
JP2022500473A (ja
Inventor
ピーター・タイ・ワー・チェン
シ・ジュン
シーウェイ・タオ
ジャン・ハオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2022500473A publication Critical patent/JP2022500473A/ja
Publication of JP2022500473A5 publication Critical patent/JP2022500473A5/ja
Application granted granted Critical
Publication of JP7412424B2 publication Critical patent/JP7412424B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2021515046A 2018-09-18 2019-09-16 Lpaアンタゴニストとしてのオキサビシクロ酸 Active JP7412424B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732588P 2018-09-18 2018-09-18
US62/732,588 2018-09-18
PCT/US2019/051272 WO2020060914A1 (en) 2018-09-18 2019-09-16 Oxabicyclo acids as lpa antagonists

Publications (3)

Publication Number Publication Date
JP2022500473A JP2022500473A (ja) 2022-01-04
JP2022500473A5 JP2022500473A5 (cg-RX-API-DMAC7.html) 2023-11-08
JP7412424B2 true JP7412424B2 (ja) 2024-01-12

Family

ID=68073221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515046A Active JP7412424B2 (ja) 2018-09-18 2019-09-16 Lpaアンタゴニストとしてのオキサビシクロ酸

Country Status (7)

Country Link
US (1) US12428430B2 (cg-RX-API-DMAC7.html)
EP (1) EP3853232B1 (cg-RX-API-DMAC7.html)
JP (1) JP7412424B2 (cg-RX-API-DMAC7.html)
KR (1) KR102788997B1 (cg-RX-API-DMAC7.html)
CN (1) CN113366000A (cg-RX-API-DMAC7.html)
ES (1) ES2941774T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020060914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102800284B1 (ko) * 2018-09-18 2025-04-23 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헵틸 산
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與lpa受體活性相關的病狀的化合物及組合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078805A1 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Polycyclic lpa1 antagonist and uses thereof
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
JP2015520202A (ja) 2012-06-20 2015-07-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Lpar拮抗薬としてのn−アルキルトリアゾール化合物
WO2017223016A1 (en) 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
JP2022500469A (ja) 2018-09-18 2022-01-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Lpaアンタゴニストとしてのシクロヘプチル酸
JP2022500470A (ja) 2018-09-18 2022-01-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Lpaアンタゴニストとしてのシクロペンチル酸

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527917A (en) 1999-11-12 2005-03-24 Biogen Inc Polycycoalkylpurines as adenosine receptor antagonists
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス,インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
WO2012078593A2 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
MA37439B1 (fr) 2012-04-27 2017-02-28 Novartis Ag Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
HK1206339A1 (en) 2012-06-20 2016-01-08 霍夫曼-拉罗奇有限公司 N-aryltriazole compounds as lpar antagonists
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのピラゾールo-架橋カルバモイルシクロヘキシル酸
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
JP7369125B2 (ja) 2017-12-19 2023-10-25 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのイソキサゾールo-架橋カルバモイルシクロヘキシル酸
PE20210655A1 (es) 2017-12-19 2021-03-31 Bristol Myers Squibb Co Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa
KR102725744B1 (ko) 2017-12-19 2024-11-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
ES2962367T3 (es) 2017-12-19 2024-03-18 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2019126087A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078805A1 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Polycyclic lpa1 antagonist and uses thereof
JP2015520202A (ja) 2012-06-20 2015-07-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Lpar拮抗薬としてのn−アルキルトリアゾール化合物
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2017223016A1 (en) 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
JP2022500469A (ja) 2018-09-18 2022-01-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Lpaアンタゴニストとしてのシクロヘプチル酸
JP2022500470A (ja) 2018-09-18 2022-01-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Lpaアンタゴニストとしてのシクロペンチル酸

Also Published As

Publication number Publication date
EP3853232B1 (en) 2023-03-01
US12428430B2 (en) 2025-09-30
KR102788997B1 (ko) 2025-03-28
ES2941774T3 (es) 2023-05-25
KR20210060546A (ko) 2021-05-26
WO2020060914A1 (en) 2020-03-26
JP2022500473A (ja) 2022-01-04
US20210317131A1 (en) 2021-10-14
EP3853232A1 (en) 2021-07-28
CN113366000A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
JP7202383B2 (ja) Lpaアンタゴニストとしてのピラゾールo-架橋カルバモイルシクロヘキシル酸
JP7427658B2 (ja) Lpaアンタゴニストとしてのシクロペンチル酸
JP7301839B2 (ja) Lpaアンタゴニストとしてのピラゾールn-連結のカルバモイルシクロヘキシル酸
JP7301840B2 (ja) Lpaアンタゴニストとしてのイソキサゾールn結合カルバモイルシクロヘキシル酸
JP7256807B2 (ja) Lpaアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール
JP7369125B2 (ja) Lpaアンタゴニストとしてのイソキサゾールo-架橋カルバモイルシクロヘキシル酸
JP7429224B2 (ja) Lpaアンタゴニストとしてのシクロヘプチル酸
JP7299892B2 (ja) Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
KR102788997B1 (ko) Lpa 길항제로서의 옥사비시클로 산
KR102726939B1 (ko) Lpa 길항제로서의 시클로헥실 산 피라졸 아졸
KR102963816B1 (ko) Lpa 길항제로서의 이속사졸 카르복실산

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220831

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231226

R150 Certificate of patent or registration of utility model

Ref document number: 7412424

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150